BioAtla (BCAB) Non-Current Debt (2020 - 2021)

BioAtla's (BCAB) quarterly Non-Current Debt came in at $682000.0 in Q2 2021, little changed quarter-over-quarter from $682000.0 in Q1 2021.

Analysis

BioAtla (BCAB) Non-Current Debt (2020 - 2021) Analysis & Trends

BioAtla (BCAB) has reported Non-Current Debt for 2 consecutive years, with $682000.0 the latest figure, recorded in Q2 2021.

For the quarter ending Q2 2021, Non-Current Debt changed N/A year-over-year to $682000.0; the trailing twelve-month figure through Jun 2021 stood at $682000.0 (changed N/A YoY), and the FY2020 full-year result was $682000.0, changed N/A from the prior year.
Non-Current Debt held at $682000.0 in Q2 2021 per BCAB's latest filing, from $682000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $682000.0 in Q4 2020 and bottomed at $682000.0 in Q4 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Amgen	206.24 Bn	192.25 Bn	7.24 Bn	57.30 Bn
2	Gilead Sciences	180.01 Bn	176.83 Bn	6.22 Bn	26.25 Bn
3	Vertex Pharmaceuticals	131.33 Bn	123.47 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.87 Bn	73.87 Bn	3.93 Bn	1.99 Bn
5	Argenx Se	60.27 Bn	55.08 Bn	1.37 Bn	-
6	Moderna	53.93 Bn	48.79 Bn	52.00 Mn	591.00 Mn
7	Alnylam Pharmaceuticals	33.17 Bn	29.86 Bn	992.69 Mn	-
8	Biogen	31.89 Bn	30.60 Bn	1.96 Bn	7.29 Bn
9	Roivant Sciences	29.12 Bn	29.12 Bn	1.16 Mn	-
10	BioAtla	2.33 Mn	2.33 Mn	-	-

Historic Data

Download Data